These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3047336)

  • 1. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
    Manni A; Bartholomew M; Caplan R; Boucher A; Santen R; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon R
    J Clin Oncol; 1988 Sep; 6(9):1456-66. PubMed ID: 3047336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
    Manni A; Santen RJ; Boucher A; Lipton A; Harvey H; Simmonds M; White D; Gordon R; Ronher T; Drago J
    Anticancer Res; 1985; 5(2):161-5. PubMed ID: 3888046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; Gordon R; Rohner T; Drago J; Wettlaufer J
    J Steroid Biochem; 1987; 27(1-3):551-6. PubMed ID: 3695494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen priming and response to chemotherapy in advanced prostatic cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner TJ; Drago J
    J Urol; 1986 Dec; 136(6):1242-6. PubMed ID: 3534315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner T; Drago J
    Anticancer Res; 1986; 6(2):309-14. PubMed ID: 3518596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.
    Dowsett M; Shearer RJ; Ponder BA; Malone P; Jeffcoate SL
    Br J Cancer; 1988 Feb; 57(2):190-2. PubMed ID: 3358910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic chemotherapy and androgen priming in patients with advanced carcinoma of the prostate. A phase II trial of the Piedmont Oncology Association.
    Muss HB; Case D; Cooper MR; Richards F; Spurr CL; Resnick MI; Zekan P; Nelson EC; Puckett JB; Pope E
    Am J Clin Oncol; 1985 Oct; 8(5):396-400. PubMed ID: 4061374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
    Bezwoda WR
    Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
    Hussain M; Wolf M; Marshall E; Crawford ED; Eisenberger M
    J Clin Oncol; 1994 Sep; 12(9):1868-75. PubMed ID: 8083710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
    Ellerhorst JA; Tu SM; Amato RJ; Finn L; Millikan RE; Pagliaro LC; Jackson A; Logothetis CJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2371-6. PubMed ID: 9815636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.
    Osborne CK; Blumenstein B; Crawford ED; Coltman CA; Smith AY; Lambuth BW; Chapman RA
    J Clin Oncol; 1990 Oct; 8(10):1675-82. PubMed ID: 2213104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
    Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
    Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation.
    Hickey D; Cant J; Soloway MS
    Urology; 1988 Jan; 31(1):38-40. PubMed ID: 2447693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.